Aurobindo Pharma Ltd 2022 AR2
The report highlights Aurobindo Pharma Limited's performance and ESG commitments for the fiscal year 2021-22. The company achieved revenues of INR 234,555 million and maintained its position as the second-largest listed Indian pharmaceutical company by revenue. Key environmental achievements include a 1.2% reduction in energy consumption and a 10% reduction in carbon emissions from the FY20 baseline. On the social front, women represented 9% of the workforce, and the company impacted over 8.64 lakh lives through CSR interventions. Additionally, the company advanced its biosimilars pipeline with two oncology biosimilar filings in Europe.
Company: Aurobindo Pharma Ltd
Sector: Health Care
Country: India
Year: 2022
Type: AR2
Pages: 322
Aurobindo Pharma Ltd
Annual Report
The report highlights Aurobindo Pharma Limited's performance and ESG commitments for the fiscal year 2021-22. The company achieved revenues of INR 234,555 million and maintained its position as the second-largest listed Indian pharmaceutical company by revenue. Key environmental achievements include a 1.2% reduction in energy consumption and a 10% reduction in carbon emissions from the FY20 baseline. On the social front, women represented 9% of the workforce, and the company impacted over 8.64 lakh lives through CSR interventions. Additionally, the company advanced its biosimilars pipeline with two oncology biosimilar filings in Europe.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Apr 1, 2021 - Mar 31, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Renewable Energy
Employees